Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
NCT04779307Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2021
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), sponsored by Takeda. Started Oct 2021; status: completed.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04779307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779307.